Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferasirox - Novartis

Next Previous
Drug Profile

Deferasirox - Novartis

Alternative Names: CGP-72670; Deferasirox; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; University Hospital Grenoble
  • Class Antianaemics; Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents; Cytochrome P 450 cyp2c8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes; Thalassaemia
  • Discontinued Malaria

Most Recent Events

  • 15 Jan 2024 Novartis completes a phase II trial in Iron overload (In adolescents, In children) in Turkey, Tunisia, Thailand, Russia, Philippines, Panama, Oman, Malaysia, Lebanon, Italy, India, Hungary, France, Egypt, Bulgaria, Belgium, USA (PO, Granules) (NCT02435212) (EudraCT2013-004739-55)
  • 17 Apr 2023 Novartis completes a phase II trial in Iron overload inFrance, Romania, Russia, Slovakia, Germany, Switzerland, and Spain (PO) (NCT03203850) (EudraCT2016-002529-12)
  • 11 Mar 2021 Novartis completes the phase II JUPITER trial for Thalassaemia (In children, In the elderly, In adolescents, In adults, In infants) in Vietnam, Thailand, Saudi Arabia, Morocco, Lebanon, Turkey and Egypt (PO) (NCT02993224)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top